Artelo Biosciences Inc (ARTL)

Sep 11, 2026, 7:00 AM EDT - 2 days ago

Artelo Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026, 9:00 AM EDT - 5 days ago

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 1, 2026, 7:00 AM EDT - 12 days ago

Artelo Biosciences Slides: Corporate presentation

2026-08-28T23:50:09.000Z - 15 days ago

Artelo Biosciences Inc trading halted, news pending

2026-08-27T12:10:57.000Z - 17 days ago

Artelo Biosciences announces 1-for-9 reverse stock split

Aug 27, 2026, 8:00 AM EDT - 17 days ago

Artelo Biosciences Announces Reverse Stock Split

2026-08-20T13:35:43.000Z - 24 days ago

Artelo secures Japan patent allowance for ART27.13 commercial formulation

Aug 20, 2026, 8:52 AM EDT - 24 days ago

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

2026-08-17T13:15:17.000Z - 27 days ago

Artelo Biosciences receives notice of allowance from USPTO

Aug 17, 2026, 8:52 AM EDT - 27 days ago

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

Artelo Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

Artelo Biosciences Earnings release: Q2 2026

2026-08-10T13:00:42.000Z - 4 weeks ago

Artelo Biosciences doses first patient in DREAM study

Jul 17, 2026, 11:00 AM EDT - 1 month ago

Artelo Biosciences Transcript: AGM 2026

2026-07-16T12:55:39.000Z - 1 month ago

Artelo Biosciences announces new ART26.12 data

Jul 16, 2026, 8:48 AM EDT - 1 month ago

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Jul 16, 2026, 8:00 AM EDT - 1 month ago

Artelo Biosciences Proxy statement: Proxy filing

Jul 16, 2026, 8:00 AM EDT - 1 month ago

Artelo Biosciences Proxy statement: Proxy filing

Jul 14, 2026, 8:47 AM EDT - 2 months ago

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

2026-07-13T13:10:08.000Z - 2 months ago

Artelo Biosciences announces results from ART27.13 nonclinical studies

Jul 13, 2026, 9:02 AM EDT - 2 months ago

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Jul 2, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Proxy statement: Proxy filing

2026-07-01T13:40:23.000Z - 2 months ago

Artelo Biosciences presents preclinical pain data for ART26.12

Jul 1, 2026, 8:42 AM EDT - 2 months ago

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Jun 30, 2026, 8:57 AM EDT - 2 months ago

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Jun 29, 2026, 8:45 AM EDT - 2 months ago

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 10, 2026, 7:38 AM EDT - 3 months ago

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Jun 5, 2026, 8:00 AM EDT - 3 months ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 8:00 AM EDT - 3 months ago

Artelo Biosciences Proxy statement: Proxy filing

Jun 5, 2026, 7:00 AM EDT - 3 months ago

Artelo Biosciences Slides: Corporate presentation

May 26, 2026, 8:00 AM EDT - 3 months ago

Artelo Biosciences Proxy statement: Proxy filing

May 20, 2026, 7:00 AM EDT - 3 months ago

Artelo Biosciences Slides: Corporate presentation

May 14, 2026, 4:05 PM EDT - 4 months ago

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

May 14, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

May 14, 2026, 7:00 AM EDT - 4 months ago

Artelo Biosciences Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Artelo Biosciences Earnings release: Q1 2026

2026-05-04T20:48:41.000Z - 4 months ago

Artelo Biosciences files $75M mixed securities shelf

May 4, 2026, 8:00 AM EDT - 4 months ago

Artelo Biosciences Registration statement: Registration filing

2026-04-28T13:43:29.000Z - 4 months ago

Artelo Biosciences announces collaboration with ScienceMachine

Apr 28, 2026, 8:25 AM EDT - 4 months ago

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

AI

2026-04-20T12:15:49.000Z - 4 months ago

Artelo Biosciences announces publication of article on ART26.12

Apr 20, 2026, 7:50 AM EDT - 4 months ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 15, 2026, 7:00 AM EDT - 5 months ago

Artelo Biosciences Slides: Corporate presentation

2026-04-07T20:25:22.000Z - 5 months ago

Artelo Biosciences files to sell 9.82M shares of common stock for holders

2026-04-07T13:09:13.000Z - 5 months ago

Artelo Biosciences regains compliance with Nasdaq

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Artelo Biosciences Registration statement: Registration filing

Apr 7, 2026, 7:50 AM EDT - 5 months ago

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Mar 30, 2026, 4:46 PM EDT - 5 months ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2026-03-30T09:39:29.000Z - 5 months ago

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

LLY NVO

2026-03-27T14:45:29.000Z - 5 months ago

Artelo Biosciences announces $11M private placement priced at-the-market

Mar 27, 2026, 10:40 AM EDT - 5 months ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2026-03-25T20:40:32.000Z - 5 months ago

Artelo announces expansion opportunity for ART27.13 in muscle preservation

Mar 25, 2026, 4:05 PM EDT - 5 months ago

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Mar 25, 2026, 7:31 AM EDT - 5 months ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

2026-03-24T21:35:16.000Z - 5 months ago

Artelo Biosciences files to sell 4.27M shares of common stock for holders

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Artelo Biosciences Slides: Corporate presentation

2026-03-20T21:20:34.000Z - 5 months ago

Artelo Biosciences files to sell 1.64M shares of common stock

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Artelo Biosciences Registration statement: Registration filing

Mar 18, 2026, 10:41 AM EDT - 5 months ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Mar 18, 2026, 8:07 AM EDT - 5 months ago

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Mar 18, 2026, 7:41 AM EDT - 5 months ago

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Feb 24, 2026, 8:00 AM EST - 6 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Feb 24, 2026, 7:00 AM EST - 6 months ago

Artelo Biosciences Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Artelo Biosciences Annual report: Q4 2025

Jan 30, 2026, 11:00 AM EST - 7 months ago

Artelo Biosciences Transcript: AGM 2026

Jan 8, 2026, 7:00 AM EST - 8 months ago

Artelo Biosciences Slides: Investor presentation

Jan 7, 2026, 7:00 AM EST - 8 months ago

Artelo Biosciences Proxy statement: Proxy Filing

Dec 23, 2025, 9:00 AM EST - 8 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Dec 11, 2025, 7:00 AM EST - 9 months ago

Artelo Biosciences Proxy statement: Proxy filing

Nov 17, 2025, 7:00 AM EST - 10 months ago

Artelo Biosciences Registration statement: Registration Filing

Nov 12, 2025, 4:00 PM EST - 10 months ago

Artelo Biosciences Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

Artelo Biosciences Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 10 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 15, 2025, 9:15 AM EDT - 11 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 11 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 11 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 11 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 1 year ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 1 year ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 1 year ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 1 year ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Artelo Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Artelo Biosciences Quarterly report: Q2 2025

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Aug 4, 2025, 7:30 AM EDT - 1 year ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Proxy statement: Proxy Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Registration statement: Registration Filing

Jul 9, 2025, 7:50 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 7, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 1 year ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis